{"id":19862,"date":"2023-12-22T08:50:39","date_gmt":"2023-12-21T19:50:39","guid":{"rendered":"https:\/\/clladvocates.nz\/?p=19862"},"modified":"2023-12-22T08:51:11","modified_gmt":"2023-12-21T19:51:11","slug":"nz-patients-contribute-to-research-for-future-treatment-for-leukaemia-in-global-studies","status":"publish","type":"post","link":"https:\/\/clladvocates.nz\/?p=19862","title":{"rendered":"NZ patients contribute to research for future treatment for leukaemia in global studies"},"content":{"rendered":"<p>At the American Society of Haematology (ASH) conference, significant research on chronic lymphocytic leukaemia (CLL) was unveiled, capturing the attention of New Zealand&#8217;s haematologists and researchers. The studies focused on the extended monitoring of a chemo-free, fixed-duration, oral treatment approach for CLL patients, offering promising insights into a potentially groundbreaking first-line therapy. This research marks a pivotal advancement in understanding CLL treatment, highlighting the potential for more effective and manageable approaches in combating this form of leukaemia.<\/p>\n<p>Please read more here: <a href=\"https:\/\/clladvocates.nz\/wp-content\/uploads\/2023\/12\/CLL_future-treatment-for-leukaemia.pdf\">Media Release &#8211; Research for Future CLL Treatment<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>At the American Society of Haematology (ASH) conference, significant research on chronic lymphocytic leukaemia (CLL) was unveiled, capturing the attention [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":19369,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[12,17],"tags":[30,47,48,49,68,85],"class_list":["post-19862","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news-media","category-featured","tag-blood-cancer","tag-chronic-lymphocytic-leukemia","tag-ibrutinib","tag-pharmac-review-panel","tag-health-select-committee-blood-cancer-cll-leukaemia","tag-government"],"jetpack_featured_media_url":"https:\/\/clladvocates.nz\/wp-content\/uploads\/2023\/04\/Pharmac_waiting_lists.jpg","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/posts\/19862","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=19862"}],"version-history":[{"count":2,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/posts\/19862\/revisions"}],"predecessor-version":[{"id":19868,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/posts\/19862\/revisions\/19868"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=\/wp\/v2\/media\/19369"}],"wp:attachment":[{"href":"https:\/\/clladvocates.nz\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=19862"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=19862"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/clladvocates.nz\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=19862"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}